Dermatology Drug Portfolios Trade Hands

Dermatology Drug Portfolios Trade Hands

by | Aug 3, 2018 1:24 pm | Pharmaceuticals

Dermatology physician practics are all the rage among private equity groups these days. Thirty deals targeting this specialty have been announced in the first seven months of 2018. All have been acquired by a private equity firm or one of their platform companies. But in the first week of August, two international pharmaceutical companies acquired portfolios of dermatology brands from the likes of Allergan plc (NYSE: AGN) and Bayer AG (BAYGn.DE). Barcelona-based Almirall, S.A. (MCE: ALM) was the only company to disclose a price in its announcement. It agreed to pay $550 million upfront for Allergan’s U.S. dermatology portfolio,  and a possible earn-out of up to $100 million based on... Read More »

Bayer’s Diabetes Care Business Fetches $1.1 Billion

by | Jun 15, 2015 7:53 pm | Other Services

Last week Bayer AG (XETRA: BAYN) agreed to sell its Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd. for €1,022 million (¥138 billion), or $1.154 billion. The sale includes the leading Contour™ portfolio of blood glucose monitoring meters and strips, as well as other products such as Breeze™2, Elite™ and Microlet™ lancing devices. The portfolio accounted for €909 million (of $1.02 billion) in sales in 2014, according to Bayer. Panasonic Healthcare Holdings was formed in September 2013 when KKR & Co. (NYSE: KKR) invested $1.67 billion in cash to gain 80% control of the healthcare division of Japan’s Panasonic Corporation. Panasonic retained 20% of the division. With... Read More »